PE20081789A1 - Composicion farmaceutica que contiene aclidino - Google Patents
Composicion farmaceutica que contiene aclidinoInfo
- Publication number
- PE20081789A1 PE20081789A1 PE2008000361A PE2008000361A PE20081789A1 PE 20081789 A1 PE20081789 A1 PE 20081789A1 PE 2008000361 A PE2008000361 A PE 2008000361A PE 2008000361 A PE2008000361 A PE 2008000361A PE 20081789 A1 PE20081789 A1 PE 20081789A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- aclidin
- composition containing
- gynostromah
- antimuscarinal
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 abstract 1
- 229940019903 aclidinium Drugs 0.000 abstract 1
- 239000000808 adrenergic beta-agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONSTA DE: A) ACLIDINIO; D) EXCIPIENTES TALES COMO LACTOSA, POLISACARIDOS, ENTRE OTROS; C) ADICIONALMENTE UN SEGUNDO MEDICAMENTO, TALES COMO AGONISTAS ß-ADRENERGICOS, GLUCOCORTICOIDES, INHIBIDORES DE PDE IV, ENTRE OTROS. DICHA COMPOSICION ES ANTAGONISTA DE RECEPTORES MUSCARINICOS, DE ADMINISTRACION INHALATORIA Y ES DE UTILIDAD EN EL TRATAMIENTO DE ESTADOS RESPIRATORIOS, O ENFERMEDADES QUE DEPENDAN DE LA ACTIVIDAD ANTIMUSCARINICA SISTEMICA, TAL COMO ESQUIZOFRENIA, GLAUCOMA, OBSTRUCCION INTESTINAL, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90284307P | 2007-02-21 | 2007-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081789A1 true PE20081789A1 (es) | 2008-12-27 |
Family
ID=39247776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000361A PE20081789A1 (es) | 2007-02-21 | 2008-02-20 | Composicion farmaceutica que contiene aclidino |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20110243924A1 (es) |
| EP (1) | EP2120936B1 (es) |
| JP (2) | JP5739616B2 (es) |
| KR (2) | KR20150038750A (es) |
| CN (2) | CN105395548A (es) |
| AR (1) | AR065392A1 (es) |
| AT (1) | ATE513547T1 (es) |
| AU (1) | AU2008217301B2 (es) |
| BR (1) | BRPI0806392A8 (es) |
| CA (1) | CA2678975C (es) |
| CL (1) | CL2008000461A1 (es) |
| CO (1) | CO6210814A2 (es) |
| CY (1) | CY1111799T1 (es) |
| DK (1) | DK2120936T3 (es) |
| EC (1) | ECSP099556A (es) |
| ES (1) | ES2367722T3 (es) |
| HR (1) | HRP20110556T1 (es) |
| IL (1) | IL200278A (es) |
| MX (1) | MX2009008825A (es) |
| MY (1) | MY153408A (es) |
| NZ (1) | NZ578473A (es) |
| PE (1) | PE20081789A1 (es) |
| PL (1) | PL2120936T3 (es) |
| PT (1) | PT2120936E (es) |
| RU (1) | RU2484821C2 (es) |
| SI (1) | SI2120936T1 (es) |
| TW (1) | TWI475994B (es) |
| UA (1) | UA98136C2 (es) |
| UY (1) | UY30901A (es) |
| WO (1) | WO2008101591A1 (es) |
| ZA (1) | ZA200904941B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| CN102639531B (zh) | 2009-08-07 | 2016-01-20 | 基因里克斯(英国)有限公司 | 噻托溴铵的无水合物 |
| WO2011095800A2 (en) * | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Analytical methods |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| EA201590030A1 (ru) * | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
| US20200054611A1 (en) | 2017-01-09 | 2020-02-20 | Gt Biopharma, Inc. | Use and composition for treating myasthenia gravis and other myasthenic syndromes |
| WO2019023318A1 (en) * | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA |
| WO2019023175A1 (en) * | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| KR102169476B1 (ko) * | 2020-05-20 | 2020-10-23 | (주)신테카바이오 | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 |
| JP7104449B2 (ja) * | 2020-05-20 | 2022-07-21 | シンテカバイオ インコーポレイティッド | 二類重症急性呼吸器症候群コロナウイルス感染症の予防または治療用組成物 |
| CN115267024B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物及其检测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
-
2008
- 2008-01-31 BR BRPI0806392A patent/BRPI0806392A8/pt not_active Application Discontinuation
- 2008-01-31 WO PCT/EP2008/000782 patent/WO2008101591A1/en not_active Ceased
- 2008-01-31 EP EP08707469A patent/EP2120936B1/en active Active
- 2008-01-31 AT AT08707469T patent/ATE513547T1/de active
- 2008-01-31 SI SI200830381T patent/SI2120936T1/sl unknown
- 2008-01-31 AU AU2008217301A patent/AU2008217301B2/en active Active
- 2008-01-31 NZ NZ578473A patent/NZ578473A/en unknown
- 2008-01-31 CA CA2678975A patent/CA2678975C/en active Active
- 2008-01-31 HR HR20110556T patent/HRP20110556T1/hr unknown
- 2008-01-31 CN CN201510633145.XA patent/CN105395548A/zh active Pending
- 2008-01-31 ES ES08707469T patent/ES2367722T3/es active Active
- 2008-01-31 US US12/528,267 patent/US20110243924A1/en not_active Abandoned
- 2008-01-31 PL PL08707469T patent/PL2120936T3/pl unknown
- 2008-01-31 CN CN200880005871A patent/CN101616670A/zh active Pending
- 2008-01-31 UA UAA200909464A patent/UA98136C2/ru unknown
- 2008-01-31 KR KR20157007787A patent/KR20150038750A/ko not_active Ceased
- 2008-01-31 PT PT08707469T patent/PT2120936E/pt unknown
- 2008-01-31 MX MX2009008825A patent/MX2009008825A/es active IP Right Grant
- 2008-01-31 KR KR1020097017243A patent/KR20090114401A/ko not_active Ceased
- 2008-01-31 MY MYPI20093444A patent/MY153408A/en unknown
- 2008-01-31 JP JP2009550665A patent/JP5739616B2/ja active Active
- 2008-01-31 DK DK08707469.6T patent/DK2120936T3/da active
- 2008-01-31 RU RU2009135078/15A patent/RU2484821C2/ru active
- 2008-02-07 UY UY0001030901A patent/UY30901A/es unknown
- 2008-02-13 CL CL200800461A patent/CL2008000461A1/es unknown
- 2008-02-20 TW TW097105887A patent/TWI475994B/zh not_active IP Right Cessation
- 2008-02-20 AR ARP080100680A patent/AR065392A1/es unknown
- 2008-02-20 PE PE2008000361A patent/PE20081789A1/es not_active Application Discontinuation
-
2009
- 2009-07-15 ZA ZA2009/04941A patent/ZA200904941B/en unknown
- 2009-08-04 EC EC2009009556A patent/ECSP099556A/es unknown
- 2009-08-06 IL IL200278A patent/IL200278A/en active IP Right Grant
- 2009-08-21 CO CO09088171A patent/CO6210814A2/es not_active Application Discontinuation
-
2011
- 2011-08-31 CY CY20111100836T patent/CY1111799T1/el unknown
-
2013
- 2013-12-05 JP JP2013252283A patent/JP2014062114A/ja active Pending
-
2014
- 2014-12-05 US US14/561,857 patent/US20150093374A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081789A1 (es) | Composicion farmaceutica que contiene aclidino | |
| MX2020008616A (es) | Rocio de fentanilo sublingual. | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| PE20120713A1 (es) | Composiciones sublinguales de dexmedetomidina y metodos para su uso | |
| MX2013011336A (es) | Composiciones farmaceuticas intranasales de benzodiazepina. | |
| UY32833A (es) | Antagonistas dp2 y usos del mismo | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| DOP2013000314A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| AR059864A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| GT200800235A (es) | Formulacion de medicamento liquida | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |